FDA OKs Ticagrelor (Brilinta) for DAPT in High-risk Stable CAD FDA OKs Ticagrelor (Brilinta) for DAPT in High-risk Stable CAD

The new indication is based on the THEMIS trial, which entered patients with CAD and type 2 diabetes without previous MI or stroke and showed clinical benefit, but also bleeding concerns.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news